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Background: A critical disadvantage for successful chemotherapy with paclitaxel (PTX) is 
its nontargeting nature to cancer cells. Folic acid has been employed as a targeting ligand of 
various anticancer agents to increase their cellular uptake within target cells since the folate 
receptor is overexpressed on the surface of such tumor cells. In this study, a novel biodegradable 
deoxycholic acid-O-carboxymethylated chitosan–folic acid conjugate (DOMC-FA) was used 
to form micelles for encapsulating the anticancer drug PTX.
Methods and results: The drug-loading efficiency, encapsulation efficiency, in vitro drug 
release and physicochemical properties of PTX-loaded micelles were investigated in detail. 
In vitro cell culture studies were carried out in MCF-7 cells, a human breast carcinoma cell 
line, with folate receptor overexpressed on its surface. An increased level of uptake of folate-
conjugated micelles compared to plain micelles in MCF-7 cells was observed, and the enhanced 
uptake of folate-micelles mainly on account of the effective process of folate receptor-mediated 
endocytosis. The MTT assay, morphological changes, and apoptosis test implied that the folate-
conjugated micelles enhanced the cell death by folate-mediated active internalization, and the 
cytotoxicity of the FA-micellar PTX (DOMC-FA/PTX) to cancer cells was much higher than 
micelles without folate (DOMC/PTX) or the commercially available injectable preparation of 
PTX (Taxol).
Conclusion: Results indicate that the PTX-loaded DOMC-FA micelle is a successful anticancer-
targeted drug-delivery system for effective cancer chemotherapy.
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Introduction
Paclitaxel (PTX), one of the most successful anticancer drugs, is the first of a new 
class of microtubule-stabilizing agents, and has demonstrated significant antitumor 
activity in clinical trials against a broad range of solid tumors, especially against 
non-small-cell lung cancer, metastatic breast cancer, and refractory ovarian cancer.1,2 
However, because of low therapeutic index and the poor aqueous solubility of 
approximately 1 µg/mL of PTX, the generally used commercial preparation of PTX 
is Taxol (Bristol-Myers Squibb, New York, NY), a concentrated solution containing 
6 mg PTX/mL of Cremophor EL (polyoxyl 35 castor oil; Sigma-Aldrich, St Louis, 
MO) and dehydrated alcohol (1:1, v/v), which is diluted 5–20-fold in normal saline 
or dextrose solution before administration.1 Unfortunately, serious side effects have 
been reported, such as hypersensitivity, neurotoxicity, nephrotoxicity, endothelial and 
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vascular muscles causing vasodilatation, labored breathing, 
and lethargy attributable to intravenous administration of the 
current Cremophor EL-based formulation.3 For this reason 
the extensive clinical application of this drug is extremely 
limited.2
Because of these problems, there is a need for the develop-
ment of  an alternate formulation of PTX with good aqueous 
solubility, targeting delivery to tumor cells, and the ability to 
reduce side effects. Accordingly, a number of alternative for-
mulations were investigated for solubilization of PTX, includ-
ing nanoparticles, liposomes, microspheres, PTX-polymer 
conjugates, dendritic polymers, implants, and water-soluble 
prodrugs.1,2,4 Although these vehicles employed have shown 
much promise for replacing the Cremophor EL-based vehicle 
for PTX delivery, approaches of actively targeting delivery of 
PTX to tumor cells have seldom been considered. Therefore, 
to improve the therapy effect and decrease the side effects 
of PTX, delivering PTX by using a targeted drug delivery 
system is a potential approach.
O-carboxymethylated chitosan (OCMC) is a kind of 
carboxymethylated derivative of chitosan, with good bio-
compatibility, bioactivity, antibacterial activity, stability 
and aqueous solution properties that have been reported 
previously.5–7 Deoxycholic acid (DOCA), a main component 
of bile acid, contains the hydrophilic moieties and the hydro-
phobic cyclopentanophenanthrene nucleus in its molecule 
and can form micelles in water because of its   amphiphilicity. 
Thus, the introduction of DOCA into the OCMC could 
induce self-association to form self-assembled micelles and 
hydrophobic drugs could be physically incorporated into the 
core of the micelles by hydrophobic interactions.
However, this kind of micelle could not escape from the 
reticuloendothelial system, and is scavenged by the mono-
nuclear phagocyte system. Moreover, the inadequate uptake 
of the micelles at tumor sites will decrease the effect of the 
administered drug dose, and nonspecific accumulation in 
healthy tissues can lead to toxic side effects that limit the 
maximum dosage that can be safely used. These constraints 
prevent drug-loaded micelles from achieving the potential 
therapeutic effect that might otherwise be attained.8 To 
achieve cancer-targeted drug delivery, several methods have 
been attempted, one strategy is the utilization of unique 
molecular markers that are specifically overexpressed within 
the cancerous tissues. It is well known that folate recep-
tor (FR), folate-binding protein, is overexpressed on the 
surface of many human epithelial cancer cells, including 
cancers of the ovary, kidney, uterus, colon, and lung, and is 
rarely found on normal cell surfaces.9–11 Folic acid (FA) is 
appealing as a ligand because it is useful for targeting cell 
membranes and enhancing endocytosis of nanoparticles via 
the FRs. Importantly, FA-conjugates, which are covalently 
derived via its γ-carboxyl group, can retain a strong affinity 
toward its receptor, and the mechanism of cellular uptake of 
FA-conjugates by FRs is similar to that of FA chemicals.12,13 
Recycling of FRs in target cells can lead to the transport of 
more FA conjugates.14 So far, many researchers have reported 
on FA-conjugated polymeric micelles, macromolecules, 
nanoparticles, and liposomes for the targeted delivery of 
anticancer agents or genes.15–18
In our previous work, OCMC was firstly hydrophobi-
cally modified with deoxycholic acid, then covalently 
bound with FA to develop a new cancer-targeted drug-
delivery system (DOMC-FA).19 In this paper, DOMC-FA 
micelles were used as a biodegradable drug carrier for 
encapsulation of PTX. The drug-loading efficiency, 
encapsulation efficiency, in vitro drug release, and other 
physicochemical properties of PTX-loaded micelles were 
investigated in detail. Its   targeting ability and cytotoxicity 
were studied by evaluating the cellular uptake, MTT assay, 
morphological changes, and apoptosis test in FR overex-
pressed MCF-7 cells among folate-conjugate micelles, 
plain micelles, and the commercially available injectable 
preparation of PTX (Taxol).
Materials and methods
Materials
DOMC and DOMC-FA conjugates were prepared in our lab 
as described previously.19 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), rhodamine B, and 
dimethyl sulfoxide (DMSO) were obtained from Sigma 
Co, Ltd, (St Louis, MO). Paclitaxel (PTX) was obtained 
from Xian Haoxuan Bio-tech Co, Ltd (Xian, China). Taxol 
injection (Anzatax Injection Concentrate, 30 mg/5 mL) was 
produced by Beijing Shiqiao Biological Pharmaceutical Co, 
Ltd, (Beijing, China). Penicillin–streptomycin, folate-free 
RPMI-1640 medium (R1145), fetal bovine serum (FBS), 
0.25% (w/v) trypsin–0.03% (w/v) EDTA solution, and 
phosphate-buffered solution (PBS) were purchased from 
Gibco BRL (Gaithersberg, MD). Propidium iodide (PI) 
and Hoechst 33342 were purchased from KeyGen Biotech-
nology (Nanjing, China). Breast cancer cell line MCF-7 
was kindly donated by the Department of Pharmacology, 
Shandong University. All reagents were analytical grades 
and used without further purification. Water was purified by 
distillation, deionization, and reverse osmosis (Milli-Q plus; 
  Millipore, Billerica, MA).
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Preparation of drug-loaded micelles
The drug-loaded micelles were prepared by a self-assembled 
method as detailed previously.19 In brief, 25 mg of DOMC 
or DOMC-FA conjugates was mixed with 5–20 mg of PTX 
in 5 mL distilled water, followed by gentle shaking at room 
temperature for 3 hours. Then the solution was sonicated 
three times using a probe-type sonifier (JY92-Ultrasonic 
Processor; Xinzhi, Linbo, China) at 90 W for 2 minutes each 
under an ice bath condition. The pulse was turned off for 
2 seconds with an interval of 4 seconds to inhibit increase in 
temperature. Then, the mixture was centrifuged at 3000 rpm 
for 20 minutes to remove the unloaded monomer and passed 
through a membrane filter (pore size: 0.45 µm;   Millipore), 
  followed by lyophilization or stored at 4°C for use. The 
content of PTX incorporated in the micelles was detected 
by high-pressure liquid chromatography (HPLC) assay after 
the disruption of the micelles and the solubilization of PTX   
in acetonitrile.
For cellular uptake studies, rhodamine B-loaded micelle 
was also prepared by the method described above. To remove 
excess amounts of rhodamine B, the micelle was transferred 
to a dialysis membrane (molecular cut off 12,000) and 
then dialyzed against distilled water for 12 hours at room 
  temperature. The content of rhodamine B was determined 
by measuring UV (UV-2102PCS; UNICO, Shanghai, China) 
absorbance at 545 nm.
Characterization of micelles
Determination of drug-loading parameters
PTX was extracted from the polymer micelles with 
  acetonitrile, then filtered with a 0.2 mm syringe filter and its 
concentration analyzed using HPLC (1100 series; Agilent, 
Santa Clara, CA). Sample solution was injected at least three 
times at a volume of 20 µL into a Phenomenex-ODS C18 
column (150 × 4.60 mm; 5 µm) preceded by a C18 guard 
column (Dikma, China). The mobile phase was a mixture 
of water and acetonitrile in the volume ratio of 53:47. The 
elution rate was 1.0 mL/min and the paclitaxel detection 
wavelength was set at 229 nm.
Compared to that of incorporated PTX as shown later 
(.2.5 mg/mL), the solubility of free PTX in water is very low 
(,1 µg/mL). So the amount of free PTX in these preparations 
was not taken into account.20
The drug concentration of PTX was calculated from stan-
dard curves. The assay was linear over the tested concentra-
tion range, and there was no interference of the polymer with 
the assay. Drug-loading efficiency (DL) and encapsulation 
efficiency (EE) were calculated as following:
 
DL%
Weight of the drug in micelles
Weight of the feedin
=
g pol lymer and drug
   % × 100
 
EE%
Weight of the drug in micelles
Weight of the feeding dr
=
u ug
   % × 100
Evaluation of particle size and zeta potential
The average particle size and size distribution of drug-
loaded micelles were determined using a Zetasizer (3000HS; 
Malvern Instruments Ltd, Malvern, UK). The polydispersity 
index range was comprised between 0 and 1. Zeta potentials 
of micelles were measured with a zeta potential analyzer 
(ZetaPALS; Brookhaven Instruments, Holtsville, NY). The 
concentration of micelles was kept constantly at 2.0 mg/mL. 
Each sample was determined in triplicate.
Transmission electron microscopy observation
The morphology and size of micelles were observed using 
a transmission electron microscope (TEM) (H-7000; 
Hitachi, Tokyo, Japan). A drop of sample solution (2 mg/mL) 
was placed onto a 300-mesh copper grid coated with carbon. 
After 2 minutes, the grid was tapped with a filter paper to 
remove surface water, air dried, and negatively stained with 
2% phosphotungstic acid for 30 seconds. The grid was dried 
at room temperature and then observed by TEM.
X-ray diffraction
X-ray diffraction (XRD) spectrometry was obtained using an 
XD-3A powder diffractometer (D/Max r-B; Rigaku, Tokyo, 
Japan). A Cu Kα radiation at 40 kV and 100 mA was used. 
Diffractograms were performed from the initial angle 2θ = 3° 
to the final angle 2θ = 50° with the steps of 0.02°, at a scan-
ning speed of 4°/minute (2θ).
In vitro drug release studies
In order to create pseudo-sink conditions, the in vitro drug 
release from micelles was determined in PBS (0.15 M, 
pH 7.4 and 6.0) containing 0.5% w/v Tween 80. One milliliter of 
drug-loaded micelles was filled into a dialysis tube   (molecular 
weight cutoff = 12,000; Spectrum®, Spectrum Laboratories, 
Inc, Rancho Dominguez, CA), and the end-sealed dialysis 
tube was immersed fully in 150 mL of the release medium 
in an erlenmeyer flask. The erlenmeyer flasks were placed 
in an incubator at 37°C ± 0.5°C with stirring at 100 rpm. At 
predetermined time intervals, 1 mL of the release medium 
was withdrawn and replaced with an equal volume of fresh 
release medium. The collected samples were lyophilized 
and then dissolved in 1 mL of mobile phase and analyzed by 
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HPLC under the same analytic condition as described above. 
The results of triplicate measurements were used to calculate 
cumulative drug release.
In vitro cell culture studies
Cell line and cell culture
MCF-7, a human breast carcinoma cell line, with FR overex-
pressed on its surface was grown in cell lines using 75 cm3 
flasks in a humidified 5% CO2/95% atmosphere incubator at 
37°C, in folate-free RPMI-1640 medium, supplemented with 
10% FBS, 100 U/mL penicillin, and 100 µg/mL   streptomycin. 
Cells grown to confluence were subcultured every other day 
after being trypsinized with 0.25% trypsin–EDTA and diluted 
to one-third in fresh growth medium.
Uptake of rhodamine B-loaded polymeric micelles  
by MCF-7 cells
To deeply understand the mechanism of micelle endocytosis 
via MCF-7 cells, the cellular uptake study was conducted 
at different conditions; MCF-7 cells were incubated 
with rhodamine B-loaded micelles in the presence or 
absence of FA in the culture medium. For fluorescence 
microscopy analysis, MCF-7 cells cultured as a monolayer 
were harvested by a brief treatment with trypsin/EDTA, 
and then were washed three times with folate-free 
RPMI-1640 medium. Aliquots MCF-7 cell suspensions were 
incubated with free rhodamine B (free R-B), plain micellar 
rhodamine B (DOMC/R-B) and FA-micellar rhodamine B 
(DOMC-FA/R-B) at a final rhodamine B concentration of 
5 µM for 0.5–4 hours at 37°C. For free folate competition 
study, 1 mM folic acid was added to the incubation medium. 
After incubation, the cells were washed three times with cold 
PBS to remove unbound fluorophores. An aliquot of cells 
was taken to be examined on a Olympus IX71 fluorescence 
microscope (Olympus, Tokyo, Japan) and photographed in 
both fluorescence and bright field modes.
Cytotoxicity assay in MCF-7 cells
The in vitro antitumor activity of drug-loaded micelles and 
free drugs were determined by MTT assay as described 
previously.21 Briefly, MCF-7 cells in their logarithmic 
growth were seeded in 96-well plates at a seeding density 
of 5000 cells/well/100 µL medium. Following attachment 
overnight, the culture medium in each well was carefully 
replaced with 150 µL of medium containing serial dilutions 
of treatment drugs. The treatments included Taxol, free-PTX 
solution (PTX), plain- and FA-targeted micelles containing 
PTX (DOMC/PTX, DOMC-FA/PTX). The concentrations 
of PTX used in the treatments ranged from 1 nM to 10 µM. 
The drug-loaded micelles were diluted with micellar   solution 
in a concentration of 0.05 mg/mL in culture medium. Cells 
were incubated with treatments for indicated times (24, 48, 
72 hours, respectively) and then the viability of the cells was 
determined using MTT assay. Fifteen microliters of 5 mg/mL 
MTT dissolved in PBS was added to each well. The plates 
were incubated for an additional 4 hours at 37°C and then 
the medium was discarded. Thereafter, 150 µL of DMSO 
was added to each well to dissolve the formazan crystals. 
The absorbance of each well was read on a microplate 
reader (Bio-Rad 680; Bio-Rad Laboratories, Hercules, CA) 
at a test wavelength of 570 nm and reference wavelength 
of 630 nm.
In this assay, all the experiments were done with ten 
parallel samples. Untreated cells, blank micellar solution and 
culture medium containing 0.1% DMSO were also tested 
as controls. Results were presented as cell inhibitory rate 
and IC50 values. The percentage of cell growth inhibition 
was calculated as follows: inhibitory rate = (A570control − 
A570sample)/A570control × 100%. The cytotoxicity of drug-loaded 
micelles was expressed as IC50 values, defined as the drug 
concentration required to inhibit growth by 50% relative to 
controls, which were calculated by using nonlinear regres-
sion analysis.
Fluorescent morphological study
The cell membrane integrity of drug-treated cells was 
assessed by monitoring the uptake of the fluorescent probe, 
PI. It is a membrane-impermeant nuclear stain and used as 
an indicator for determining the cell membrane integrity. 
For determining the PI uptake, MCF-7 cells were seeded 
into 6-well culture plates at a density of 1.5 × 105 cells per 
well and attached for 24 hours. Cells were then incubated 
with medium containing drug solution or micelles at a total 
PTX concentration of 20 nM for 48 hours. The control group 
was treated with drug-free culture media. After washing with 
PBS for three times, the cells were collected and stained with 
PI (100 µg/mL, 0.5 mL) at 37°C for 10 minutes in the dark. 
Cells were washed twice following staining to remove the 
unbound PI. An aliquot of these suspensions was placed on 
the coverslip and observed under an inverted fluorescence 
microscope (Olympus IX71).
Hoechst 33342 staining
Nuclear morphologies of MCF-7 cells with different treat-
ments were investigated by the Hoechst 33342 staining 
method. MCF-7 cells with different treatments were incubated 
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for 48 hours. At the end of the treatment period, the control 
(untreated) and treated cells were harvested and washed twice 
with cold PBS. Then, the cells were collected and stained 
with Hoechst 33342 (10 µg/mL) at 37°C for 20 minutes in 
the dark and the stained cells were photographed using the 
reverse fluorescence microscopy (Olympus IX71).
Statistical analysis
All the experimental data were presented as means ± standard 
deviation and analyzed using one-way analysis of variance 
and Student’s two-tailed t-test. Statistical significance was 
determined as P , 0.05.
Results and discussion
Preparation of PTX loaded micelles
The self-assembled method appears to be particularly suitable 
for the incorporation of PTX into DOMC or DOMC-FA 
micelles. Drug-loading efficiency (DL) and encapsulation 
efficiency (EE) were measured by a validated HPLC assay. 
The detailed effects of drug-to-polymer ratio on DL and EE 
are shown in Table 1. When the initial feeding ratio of PTX 
to polymer increased from 5:25 to 15:25 (w/w), the amount 
of PTX introduced into DOMC-FA micelles significantly 
increased from 15.57 wt% to 33.61 wt%. When the initial 
feeding ratio of PTX to polymer exceeded 20:25, the 
precipitation of unloaded PTX in the aqueous medium was 
observed during the preparation of drug-loaded micelles, 
which resulted in the decrease of EE and the increasing trend 
of DL for sharp decline. Considering the resource scarcity and 
expense of PTX, a high drug-encapsulation efficiency will be 
beneficial in reducing the final product cost. Therefore, the 
optimal feeding ratio of PTX to DOMC-FA was finalized as 
15:25, which corresponded to 33.61% DL and 84.43% EE. 
Unless specified, this ratio was used throughout the following 
studies. Similar results were also obtained for the DOMC 
micelles. It is also worth noting that the size of the drug-
loaded micelles was not significantly affected by the feeding 
ratio in the range of 5:25 to 20:25. This finding implied that 
the polymer micellar self-aggregates provided sufficient 
molecular space within the core itself and thus could achieve 
a high degree of drug loading without a significant increase 
in the micellar size. Additionally, the relatively steady zeta 
potential values observed as feed ratio increased suggested 
that the stability of this micelle system was unaffected with 
increased PTX in micelles.
Compared with the intrinsic solubility of PTX, when 
PTX was loaded into micelles, the solubility of PTX in water 
increased many times. For instance, with the drug-loading 
efficiency of 33.61 wt%, the effective concentration of PTX 
could be 2.53 mg/mL, which is 8400 times higher than its 
inherent water solubility of 0.3 µg/mL.22 This observation 
confirmed the presence of hydrophobic cores and the highly 
hydrophobic paclitaxel functions as a hydrophobe in the 
core-forming polymer, therefore, such a high concentration 
of PTX in water could be achieved.23
Characterization of drug-loaded micelles
The size and size distribution of drug-loaded micelles were 
characterized by Zetasizer and exhibited a mean particle 
diameter of about 224–356 nm for the different formulations 
(Table 1). The micelles were a unimodal size distribution and 
the polydispersity indices were relatively low (0.154–0.328), 
implying a narrow size distribution for all formulations. The 
Zetasizer results of three batches of micelles had no sub-
stantial difference, which demonstrated that the preparation 
process was reproducible and stable. TEM was used to visual-
ize directly the size and morphology of drug-loaded micelles 
(Figure 1). Smooth sphere morphology and a uniform size 
distribution were observed for PTX-loaded micelles. The 
mean diameter of micelles appeared to be not consistent with 
the results determined by Zetasizer measurement, which was 
probably caused by the different mechanisms of the two meth-
ods. Since the Zetasizer method involves the measurement 
of size in the aqueous state, micelles were highly hydrated 
and the diameters detected by Zetasizer were ‘hydrated diam-
eters’, which were usually larger than their genuine diameters. 
Table 1 Properties of drug-loaded micelles (n = 3)
Polymer Feed weight ratio  
(drug:polymer (w/w))
EE (%) DL (%) Mean particle diameter  
(nm)
Zeta potential 
(mV)
DOMC-FA 5:25 92.21 ± 1.43 15.57 ± 0.63 224.8 ± 11.2 −19.4 ± 1.1
10:25 89.34 ± 2.51 26.33 ± 0.74 241.1 ± 9.1 −18.8 ± 1.2
15:25 84.43 ± 3.66 33.61 ± 0.96 258.2 ± 12.4 −17.3 ± 0.7
20:25 66.32 ± 1.74 34.67 ± 1.21 265.7 ± 17.9 −16.9 ± 0.9
DOMC 10:25 70.31 ± 1.02 21.93 ± 1.34 322.5 ± 22.6 −18.1 ± 1.3
15:25 64.66 ± 1.06 27.95 ± 0.33 356.6 ± 40.7 −16.6 ± 0.6
Abbreviations: DL, drug-loading efficiency; DOMC, deoxycholic acid-O-carboxymethylated chitosan; EE, encapsulation efficiency; FA, folic acid.
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Whereas, TEM images obtained the size at the dried state 
of the sample. This implies that the size observed by TEM 
method was smaller than their real diameters.
Zeta potential, the electric potential at the plane of 
shear, is an important parameter to predict the physical 
storage stability of colloidal systems. A higher zeta potential 
value may provide a repelling force between the micelles, 
indicating the better stability of this colloidal system.23 
As shown in Table 1, all the drug-loaded micelles had 
relatively high negative zeta potentials of around −20 mV . 
The negative zeta potential indicated that the micelle surface 
was negatively charged. This may be due to the availability 
of free carboxyl groups on the polymer, which implied 
that negative-charged carboxymethylated chitosan covered 
the micelles. In general, the zeta potential values less than 
−30 mV signify long-term stability of aqueous dispersion. 
However, despite a zeta potential above the critical value of 
−30 mV , micelles can have the same long-term stability, in 
case the sterical hindrance layer is sufficiently thick.24 In our 
study, the drug-load micelles were stable with good fluidity 
when sealed and stored under conditions such as refrigeration 
or at room temperature for three months. The appearance and 
drug-loading efficiencies hardly changed.
To confirm the existence of PTX in the polymeric 
micelles, WAXD analysis was conducted for PTX, blank 
micelles, PTX-loaded micelles, and the physical mixture 
of blank micelles and PTX, respectively. As shown in 
  Figure 2, the diffraction curve of PTX exhibited a intense 
peak at 2θ equals 5.56°, 8.92°, 10.08°, 10.76°, 11.20°, 
12.36°, 13.88°, and numerous small peaks between 15° and 
25° (Figure 2A). DOMC and DOMC-FA gave two intense 
peaks around 2θ of 16° and 22° (Figure 2D and E). When 
PTX was physically mixed with DOMC-FA, typical crystal 
peaks of PTX and modified chitosan were still observed 
(Figure 2B and C). However, the typical crystal peaks of PTX 
were not observed in the WAXD patterns from samples of 
PTX-loaded micelles, but they had two peaks similar to those 
of the blank micellar system (Figure 2F and G). Therefore, it 
can be concluded that PTX molecules were mixed uniformly 
with polymer molecules or PTX existed inside micelles in 
an amorphous state.
In vitro drug release studies
In this study, pH 7.4 and pH 6.2 PBS were selected to simulate 
the environment of blood and internal environment of tumor  Figure  1  TEM  micrographs  showing  surface  property  of  drug-loaded  micelles. 
(A) DOMC/PTX; (B) DOMC-FA/PTX.
Abbreviations: DOMC, deoxycholic acid-O-carboxymethylated chitosan; FA, folic 
acid; PTX, paclitaxel; TEM, transmission electron microscopy.
0
A
B
C
D
E
F
G
10 20 30 40 50
Figure 2 WAXD spectra of (A) PTX; (B) DOMC + PTX; (C) DOMC-FA + PTX; 
(D) DOMC; (E) DOMC-FA; (F) DOMC/PTX; (G) DOMC-FA/PTX.
Abbreviations: DOMC, deoxycholic acid-O-carboxymethylated chitosan; FA, folic 
acid; PTX, paclitaxel; WAXD, wide-angle X-ray diffraction.
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cells, respectively.25 The release medium contained 0.5% w/v 
Tween 80, in which the solubility of PTX was 32.6 µg/mL, 
therefore good sink conditions were respected. In addition, 
prior to conducting release assays, PTX released from 
stock solution was investigated as controls. It was found 
that about 100% of nonencapsulated drug was released 
after approximately 4 hours. This suggested that free drugs 
could freely diffuse through the dialysis membrane. Figure 3 
represents the in vitro cumulative release profiles of PTX 
from different formulations and reveals that the release 
profiles of PTX in the different pH environment were similar. 
In contrast with the drug’s release from stock solution, there 
was a pronounced time prolongation of the drug’s release 
from micelles. For example, only about 80 wt% PTX was 
released in 192 hours (PTX both in DOMC and DOMC-FA 
micelles). The drug-loaded DOMC and DOMC-FA micelles 
were a complex system, so that DOMC degraded very slowly 
and released the drug in a sustained manner. This result 
showed that the micelle carrier could not only solubilize 
the poorly soluble drug’s, but also sustain controlled drug 
release. Moreover, these profiles showed a burst release of 
about 15% drug’s during the first 12 hour of incubation, 
which was probably due to the nonencapsulated drugs and 
drug diffusion close to the surface of micelles.
The drug cumulative release rates showed slight pH 
dependence, for instance, the PTX cumulative release rates 
increased from 79% at pH 7.4 to 95% at pH 6.2 (PTX in 
DOMC-FA micelle). One of the reasons for the characteris-
tic of pH sensitivity could be that at low pH, –NH2 groups 
on the chitosan backbone can be easily protonated and the 
micelles swell, which promotes drug release. This observa-
tion indicated that the micelles could release more drugs in 
tumor tissues.
In vitro cell culture studies
Cellular uptake studies in MCF-7 cells
The cellular uptake of nontargeted and FA-targeted micelles 
was evaluated in human breast carcinoma cell, MCF-7. These 
cancer cells are FRs overexpressing and were studied with 
folate-mediated polymer formulations previously.26
To investigate the effect of time on the FA-targeted 
micelles uptake by FR-bearing cells, MCF-7 cells were 
incubated with free rhodamine B (free R-B), plain 
micellar rhodamine B (DOMC/R-B) and FA-micellar 
rhodamine B (DOMC-FA/R-B) for various periods and 
visualized using fluorescence microscopy. As shown in 
Figure 4, cellular uptake of free R-B was scarcely increased 
during incubation with cell monolayers. However, micellar 
rhodamine B showed significant increase of cellular 
uptake with MCF-7 cells as the time went on. Especially, 
DOMC-FA/R-B had a marked increase in cellular uptake 
compared to DOMC/R-B after 0.5 or 2 hours incubation 
with MCF-7 cells because of the effective process of 
FR-mediated endocytosis and recycling of FRs after 
internalization. However, uptake rate of DOMC-FA/R-B 
declined after 2 hours of incubation. This decline of 
endocytosis presumably resulted from saturation of 
FR-mediated internalization of FA-micelles.
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Figure 3 In vitro release of PTX from micelles in PBS (pH 7.4 and 6.2) containing 0.5% w/v Tween 80. In vitro release kinetics were carried out at 37°C ± 0.5°C by the 
dialysis bag technique. PTX release from stock solution was investigated as a control.
Note: Data as mean ± SD, n = 3.
Abbreviations: DOMC, deoxycholic acid-O-carboxymethylated chitosan; FA, folic acid; PBS, phosphate-buffered saline; PTX, paclitaxel; SD, standard deviation.
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The role of cell surface FRs in polymer binding 
was evaluated further by incubating MCF-7 cells with 
  DOMC-FA/R-B in the presence of 1 mM free FA used 
as a competitive inhibitor of cellular uptake. As shown 
in Figure 4D and E, 1 mM free FA significantly reduced 
the rhodamine B uptake in MCF-7 cells incubated with 
  DOMC-FA/R-B compared with Figure 4C, but had no effect 
in reducing rhodamine B uptake in the case of DOMC/R-B 
compared with Figure 4B. The observations showed that the 
uptake of DOMC-FA/R-B could be inhibited by the pres-
ence of free FA, and suggested that the FA-micellar might 
be endocytosed via the FR.
Figure 4 Uptake of free rhodamine B (R-B), R-B-loaded DOMC, and DOMC-FA micelles and effect of free FA on uptake of the two micelles in MCF-7 cells at different times. 
(A) free R-B; (B) DOMC/R-B; (C) DOMC-FA/R-B; (D) DOMC/R-B plus 1 mM free FA; (E) DOMC-FA/R-B plus1 mM free folic acid.
Abbreviations: DOMC, deoxycholic acid-O-carboxymethylated chitosan; FA, folic acid; PBS, phosphate-buffered saline; PTX, paclitaxel.
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Cytotoxicity assay in MCF-7 cells
It was previously reported that both carboxymethyl chitosan 
and FA had no significant cytotoxicity. Here, the cytotoxicity 
mediated by carboxymethyl chitosan conjugated with deoxy-
cholic acid and FA-based micelles (DOMC and DOMC-FA) 
was measured by MTT assay (data not shown). No signifi-
cant difference was found in cell viability whether the cells 
were treated with micelles or not. Therefore, it confirms 
the proposal that the micelles act merely as vehicles for the 
drug. Any cytotoxicity observed thus mainly attributed to 
the effects of the released drug alone. Hence, these polymer 
micelles are expected to be safe for biomedical applications. 
Our previous studies have shown that folate-functionalized 
micelles can significant increase micellar uptake in tumor 
cells, and whether increased cellular accumulation of drug-
loaded micelles increase their cytotoxicities in tumor cells. 
Here, we determined the cytotoxic activities of PTX in 
polymer micelles with folate functionalized or not against 
MCF-7 cells.
The cytotoxicity of PTX in plain micelles (DOMC/PTX) 
and FA-micellar PTX (DOMC-FA/PTX) was investigated 
and compared with that of the free PTX and Taxol injection 
using MCF-7 cells. Figure 5 shows that drug-loaded poly-
meric micelles exhibited similar activity to those observed 
with Cremophor EL-base commercial formulation (Taxol) 
and the free PTX in inhibiting the growth of MCF-7 cells 
and indicates that PTX remained biologically active after 
being incorporated into DOMC or DOMC-FA micelles. 
The IC50 values of free PTX, Taxol, DOMC/PTX, and 
DOMC-FA/PTX against MCF-7 cells for 72 hours were 
14.01 ± 0.5 nM, 10.67 ± 1.1 nM, 11.78 ± 0.8 nM, and 
6.61 ± 0.9 nM,   respectively (Table 2). Compared with 
DOMC/PTX, the cytotoxicity of which was more likely 
induced by PTX itself, Taxol showed strong cytotoxicity, 
which may be attributed partially to the use of Cremophor 
EL vehicle. FA-micellar PTX exhibited superior cytotoxic 
activities (about two times higher) to plain micellar PTX. 
This revealed that folate moieties in DOMC-FA/PTX micelles 
played an important role in enhancing a cytotoxic effect 
by binding of the micelles with FRs on MCF-7 cells, and 
subsequently increasing their intracellular uptake via FR-
mediated endocytosis. Increased internalization explained the 
improved cytotoxicity of the FA-micellar PTX to tumor cells. 
Free PTX shows less cytotoxicity compared with the micellar 
PTX, resulting from the reduced cellular uptake of PTX.
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Figure 5 Cytotoxicity of different formulations containing PTX against MCF-7 cells after treatment for 72 hours. Cells treated with growth medium and blank micelles were 
used as respective controls.
Notes: Data as mean ± SD, n = 10 wells. *P , 0.05; **P , 0.01: significantly different from the control group (free PTX); #P , 0.05; ##P , 0.01: significantly different from 
the DOMC/PTX formulation.
Abbreviations: DOMC, deoxycholic acid-O-carboxymethylated chitosan; FA, folic acid; PTX, paclitaxel; SD, standard deviation.
Table 2 The IC50 values (nmol/L) of various formulations of PTX 
against MCF-7 cells for 24, 48, and 72 hours
Formulations 24 hours 48 hours 72 hours
Free PTX 23.54 ± 1.3 19.02 ± 0.8 14.01 ± 0.5
Taxol 20.52 ± 0.7* 14.38 ± 1* 10.67 ± 1.1**
DOMC/PTX 22.46 ± 1.2* 14.24 ± 0.4** 11.78 ± 0.8**
DOMC-FA/PTX 15.48 ± 0.9*,# 9.89 ± 0.6**,## 6.61 ± 0.9**,##
Notes: *P , 0.05; **P , 0.01: significantly different from the control group (free 
PTX); #P , 0.05; ##P , 0.01: significantly different from the DOMC/PTX formulation. 
Data as mean ± SD, n = 10 wells.
Abbreviations:  DOMC,  deoxycholic  acid-O-carboxymethylated  chitosan; 
FA, folic acid; PTX, paclitaxel; SD, standard deviation.
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Figure 6 PTX induced morphology changes in MCF-7 cells. Cells were treated with PTX in solution or in drug-loaded micelles containing total PTX concentration of 20 nM 
for 48 hours. Then, PI staining assay was examined. Right panels indicate cells visualized in the fluorescence mode; left panels indicate the same fields in the bright field mode. 
(a) and (A) Control; (b) and (B) PTX solution; (c) and (C) Taxol; (d) and (D) DOMC/PTX; (e) and (E) DOMC-FA/PTX.
Abbreviations: DOMC, deoxycholic acid-O-carboxymethylated chitosan; FA, folic acid; PI, propidium iodide; PTX, paclitaxel.
IC50 values of various formulations of PTX against 
MCF-7 cells for different times were presented in Table 2. The 
results showed that PTX formulations inhibited MCF-7 cell 
growth in a time-dependent manner. In addition, significantly 
lower IC50 values were observed in cells treated with DOMC-
FA/PTX than any other formulations. Compared with plain 
micellar PTX, higher growth inhibition of FA-micellar PTX 
in the MCF-7 cells was mainly because of the effective pro-
cess of receptor-mediated endocytosis and recycling of FRs 
after internalization.27 DOMC-FA/PTX micelles can escape 
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from the endolysosomal pathway and accumulate in tumor 
cells. Following entry, micelles are retained in the cytoplasm 
and act as intracellular drug depots, which slowly release 
the encapsulated therapeutic agent in the cellular cytoplasm 
as described in Figure 3, thus, resulting in enhancement of 
therapeutic efficacy in tumor cells.
Fluorescent morphological study
Figure 6 shows the morphological images of various formu-
lations of PTX against MCF-7 cells for 48 hours. The cells 
were polygonal, cellular skeletons and nucleoli were evident 
under control conditions (Figure 6A). However, marked 
morphological changes in the cells were observed, including 
cell shrinkage, rounding and nuclear fragmentation after the 
cells were exposed to PTX formulations. In addition, more 
obvious changes and more cell death in micellar PTX were 
observed in contrast to free PTX or Taxol treatments. To 
further assess the cell membrane integrity induced by various 
formulations of PTX in MCF-7 cells, PI assay was conducted 
and photographed in the fluorescence mode. As shown in 
Figure 6A–E, the results of PI staining were consistent with 
those of the above studies. FA-micellar PTX obviously 
exhibit more cell death than any other treatments.
The investigation of apoptosis in 
MCF-7 cells
PTX is a naturally occurring antimitotic agent that has been 
shown to induce cell death by apoptosis subsequent to micro-
tubule disruption. In order to elucidate PTX-loaded micelles 
induced-apoptosis in MCF-7 cells, Hoechst staining of nuclei 
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Figure 7 Nuclear morphologies of MCF-7 cells using Hoechst 33342 staining. Cells were treated with PTX in solution or in drug-loaded micelles containing total PTX 
concentration of 20 nM for 48 h. (A) Control; (B) PTX solution; (C) Taxol; (D) DOMC /PTX; (E) DOMC-FA/PTX.
Abbreviations: DOMC, deoxycholic acid-O-carboxymethylated chitosan; FA, folic acid; PTX, paclitaxel.
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was observed after different treatments. As shown in Figure 7, 
the nuclei of the control MCF-7 cells were homogeneously 
stained like that of cytoplasm (Figure 7A), while those of the 
cells treated with the PTX solution or PTX-loaded micelles 
exhibited chromatin condensation and nuclear fragmentation 
(Figure 7B–E), which were typical apoptotic features of PTX 
induced apoptosis in MCF-7 cells.28 The photos obviously 
showed that MCF-7 cells treated with PTX-loaded micelles 
induced more cell death than those treated with free PTX 
or Taxol. Otherwise, the nucleus of the cells treated with 
PTX-loaded micelles split more than those treated with PTX 
solution. These results indicated that the micellar PTX had an 
enhanced apoptosis effect in MCF-7 cells, and especially, the 
FA-micellar had a higher effect than plain micelles because 
of the overexpression of FRs on the surface of MCF-7 cells, 
which significantly enhance the uptake of the FA-micellar 
via FR-mediated endocytosis. The above results were in 
agreement with the results of MTT assay.
Conclusion
In this study, PTX-loaded DOMC-FA micelles were success-
fully prepared as a novel drug-targeting system. The superior 
features of the PTX-loaded DOMC-FA micellar system 
over other polymeric micelles were its high drug-loading 
efficiency (33.61%), high encapsulation efficiency (84.43%), 
and increased solubility of PTX (2.53 mg/mL). There was an 
increased level of uptake of folate-conjugated micelles com-
pared with plain micelles in FR overexpressed human breast 
cancer cells, MCF-7 cells, and the uptake mainly on account 
of the effective process of FR-mediated endocytosis. The MTT 
assay, morphological changes and apoptosis test implied that 
the folate-conjugated micelles enhanced the cell-killing effect 
by folate-mediated active internalization, and the cytotoxicity 
of the FA-micellar PTX (DOMC-FA/PTX) to cancer cells was 
much higher than micelles without folate (DOMC/PTX) or the 
commercially available injectable preparation of PTX (Taxol). 
In addition, the MTT assay showed that the blank micelles were 
far less toxic than the Cremophor EL vehicle. The results of 
this research demonstrated the folate-conjugated micelles could 
be beneficial in treatment of solid tumors by targeting delivery 
of micellar PTX into the tumor cells and further reducing side 
effects and toxicities of the drugs. Further studies are in progress 
to research tissue distribution properties and in vivo therapy 
efficacy of this tumor-targeted drug-delivery system.
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